The global leader in implantable hearing solutions, Cochlear Limited (ASX:COH) has obtained approval from US FDA for four new products- Nucleus® Kanso® 2 Sound Processor, Custom Sound® Pro fitting software, Nucleus® 7 Sound Processor for Nucleus 22 implant recipients, and the Nucleus® SmartNav system.
COH shall commercially release all four new systems in the United States and Western Europe in the upcoming few months after local approvals.
Post announcement on 3 July 2020, COH quoted at A$205.640, up by 6.721% at AEST 11:57 AM.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.